Global Multiple Myeloma Drugs Market 2015-2019

Global Multiple Myeloma Drugs Market 2015-2019 is a new market research publication announced by Reportstack. Multiple myeloma is a common cancer that affects the plasma cells, a type of white blood cell. It begins in the plasma cells of bone marrow. The primary function of the plasma cells is to combat infections by producing antibodies, which attack germs after recognizing them. In multiple myeloma these plasma cells become malignant, it causes the production of a defective protein, which grows uncontrollably. This protein moves into the bones and cause tumors. Myeloma occurs when the malignant cells form a tumor. According to the Multiple Myeloma Research Foundation, the disease has been classified into six distinct stages: Pain in bone, vulnerability to infections, increased restlessness, kidney and urination ailments, fatigue, increase in thirst, loss of appetite and loss in weight. The disease can be diagnosed by a series of tests. The initial evaluation consists of a blood test, urine test and a bone marrow biopsy. X-ray, MRI scan, CT- scan and PET scan are other tests to diagnose multiple myeloma. Genomic testing is also carried out to confirm the presence of multiple myeloma in the suspected patients.
The analysts forecast the Global Multiple Myeloma Drugs market to grow at a CAGR of 8.50 percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the Global Multiple Myeloma Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of multiple myeloma. 
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Multiple Myeloma Drugs market. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. 
Key Regions
• Americas 
• APAC
• EMEA
Key Vendors
• Celgene
• Johnson & Johnson 
• Novartis 
• Onyx Pharmaceuticals
• Sanofi
• Takeda Pharmaceutical
Other Prominent Vendors
• AB Science
• Abbvie
• Aeterna Zentaris
• Amgen 
• Bristol Myers Squibb
• Cephalon 
• Daiichi Sankyo
• Genta
• Merck Sharp and Dohme
• Oncotherapeutics
• PharmaMar
• Teva 

Market Driver
• Presence of Unmet Needs
• For a full, detailed list, view our report
Market Challenge
• High Cost of Treatment
• For a full, detailed list, view our report
Market Trend
• Growing Public Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Companies Mentioned
Celgene, Johnson & Johnson , Novartis , Onyx Pharmaceuticals, Sanofi, Takeda Pharmaceutical, AB Science, Abbvie, Aeterna Zentaris, Amgen , Bristol Myers Squibb, Cephalon , Daiichi Sankyo, Genta, Merck Sharp and Dohme, Oncotherapeutics, PharmaMar, TevaTo view the table of contents and know more details please visit Global Multiple Myeloma Drugs Market 2015-2019